Disease Activity and Adverse Events in Patients with ANCA-Associated Vasculitides Undergoing Long-Term Dialysis

• Published in: Clinical journal of the American Society of Nephrology 2021-11, Vol.16 (11), p.1665-1675
• Main Authors: Kauffmann, Maëlis, Bobot, Mickaël, Robert, Thomas, Burtey, Stéphane, Couvrat-Desvergnes, Grégoire, Lavainne, Frédéric, Puéchal, Xavier, Terrier, Benjamin, Quéméneur, Thomas, Faguer, Stanislas, Karras, Alexandre, Brunet, Philippe, Couchoud, Cécile, Jourde-Chiche, Noémie
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - metabolism; Cause of Death; Female; Follow-Up Studies; France - epidemiology; Granulomatosis with Polyangiitis - complications; Granulomatosis with Polyangiitis - drug therapy; Granulomatosis with Polyangiitis - mortality; Human health and pathology; Humans; Immunosuppressive Agents - therapeutic use; Incidence; Infections - epidemiology; Infections - mortality; Kidney Transplantation; Life Sciences; Male; Microscopic Polyangiitis - complications; Microscopic Polyangiitis - drug therapy; Microscopic Polyangiitis - mortality; Middle Aged; Neoplasms - epidemiology; Neoplasms - mortality; Original; Progression-Free Survival; Recurrence; Registries; Remission Induction; Renal Dialysis; Renal Insufficiency, Chronic - etiology; Renal Insufficiency, Chronic - therapy; Retrospective Studies; Survival Rate; Urology and Nephrology
• ISSN: 1555-9041; 1555-905X; 1555-905X
• DOI: 10.2215/CJN.03190321

Kidney impairment of ANCA-associated vasculitides can lead to kidney failure. Patients with kidney failure may suffer from vasculitis relapses but are also at high risk of infections and cardiovascular events, which questions the maintenance of immunosuppressive therapy. Patients with ANCA-associated vasculitides initiating long-term dialysis between 2008 and 2012 in France registered in the national Renal Epidemiology and Information Network registry and paired with the National Health System database were included. We analyzed the proportion of patients in remission off immunosuppression over time and overall and event-free survival on dialysis (considering transplantation as a competing risk). We compared the incidence of vasculitis relapses, serious infections, cardiovascular events, and cancers before and after dialysis initiation. In total, 229 patients were included: 142 with granulomatous polyangiitis and 87 with microscopic polyangiitis. Mean follow-up after dialysis initiation was 4.6±2.7 years; 82 patients received a kidney transplant. The proportion of patients in remission off immunosuppression increased from 23% at dialysis initiation to 62% after 5 years. Overall survival rates on dialysis were 86%, 69%, and 62% at 1, 3, and 5 years, respectively. Main causes of death were infections (35%) and cardiovascular events (26%) but not vasculitis flares (6%). The incidence of vasculitis relapses decreased from 57 to seven episodes per 100 person-years before and after dialysis initiation ( =0.05). Overall, during follow-up, 45% of patients experienced a serious infection and 45% had a cardiovascular event, whereas 13% experienced a vasculitis relapse. The proportion of patients with ANCA-associated vasculitis in remission off immunosuppression increases with time spent on dialysis. In this cohort, patients were far less likely to relapse from their vasculitis than to display serious infectious or cardiovascular events. This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2021_11_08_CJN03190321.mp3.